Table 4
Primary outcome measures
| Nitric oxide | Dexamethasone | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Controls | RR | 95% CI | Treatment | Controls | RR | 95% CI | ||
| Deaths | 10 (50%) | 7 (32%) | 1.57 | 0.76-3.38 | 9 (43%) | 8 (38%) | 1.13 | 0.54-2.36 | |
| CLD | 10 (50%) | 14 (64%) | 0.79 | 0.44-1.33 | 11 (52%) | 13 (62%) | 0.85 | 0.48-1.44 | |
| CLD (survivors) | 10 (100%) | 14 (93%) | 1.07 | 0.71-1.37 | 11 (92%) | 13 (100%) | 0.92 | 0.67-1.28 | |
| CLD/death | 20 (100%) | 21 (95%) | 1.05 | 0.84-1.25 | 20 (95%) | 21 (100%) | 0.95 | 0.79-1.18 | |
-
RR = relative risk; CI = confidence intervals.
